--> jQuery(window).scroll(function() { checkStick(); }); var mbannerid = '#div-gpt-ad-1563273235586-0'; var mfooterid = '#footermobilebanner'; var dfooterid = '#div-gpt-ad-1563274691467-0'; // Desktop sticky check function checkStick() { var launched = false; if (jQuery(window).height() > 500) { if (!jQuery('#dfp_stickyfooter').hasClass("closed")) { if (jQuery('#dfp_stickyfooter > div').length) { if (!jQuery('#dfp_stickyfooter > div').hasClass("cog-mb-sticky")) { var width = jQuery('#dfp_stickyfooter > div > iframe').width(); var height = jQuery('#dfp_stickyfooter > div > iframe').height(); if (parseInt(width) > 0) { launched = true; jQuery('#dfp_stickyfooter').attr('style', 'height: '+(height+30)+'px;').addClass('opened'); jQuery('#dfp_stickyfooter').append(''); jQuery('#dfp_stickyfooter > div').addClass('cog-mb-sticky floating footer'); jQuery('#dfp_stickyfooter > div').attr('style', 'position:absolute; bottom:0;'); jQuery('#dfp_stickyfooter svg.close').on('click', function() { jQuery(this).parent().removeClass('opened').addClass('closed'); }); } } } } } if (!launched) { // Ad not ready yet window.setTimeout(checkStick, 250); } } jQuery(document).ready(function() {checkStick();}); -->

This site is intended for health professionals only

Home > Reviews & Research > Cancer Research trials Glaxo drug

Published on 20 May 2009

Share this story:

RELATED ARTICLES

Cancer Research trials Glaxo drug

teaser

A GlaxoSmithKline drug is being trialled as part of a programme to increase the number of treatments available to UK cancer patients.

Cancer Research UK is sponsoring tests of the aurora kinase inhibitor 1070916A at the Institute of Oncology at St James’s University Hospital and the Experimental Cancer Medicine Centre in London.

It is the first patient-ready drug to enter Cancer Research UK’s Clinical Development Partnerships (CDP) programme. If it is successful, further trials may follow.

Says Dr Victoria John, head of clinical partnerships: “This deal brings our CDP portfolio to three and the total number of new drugs in our early preclinical and clinical pipeline to over 40, something we believe is testament to the specialist skills and capability of our drug-development team.”

The programme, which enables companies to retain rights to the drug throughout the development programme, is an alternative to traditional outlicensing.

Copyright Press Association 2009

GlaxoSmithKline

Most read

1

Oral vitamin A could become an alternative to isotretinoin for acne

2

Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan

3

Amino acids supplement reduces muscle wasting and improves gut function in critically ill

4

Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest

5

Launch of the new Hospital Pharmacy Europe Mobile App

Be in the know

Subscribe to Hospital Pharmacy Europe newsletter and magazine

Subscribe

Share this story:

RELATED ARTICLES

x